AKL4 (APPA) Data

AKL4 (aka APPA) is associated with a decrease in pain associated with OA.

There has also been evidence of disease modification in controlled animal studies and notable improvements in mobility in human named patient subjects.

Canine Trials

Client owned dogs diagnosed with established naturally occurring OA

  • 32 Canine OA patients – 11 week study: significant pain relief
  • 80 Canine patients – 5 week study: significant benefits over standard of care Meloxicam

Rat Meniscal Tear Studies

  • Gold standard model
  • Significant disease modification
  • Significant pain relief

Anecdotal Experience

  • Refractory human subjects
  • Reduced pain and no reported adverse events
  • Patient reported improvement in QoL